🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to health experts.

A Global Challenge

The sexually transmitted infection are on the rise globally, with estimates suggesting over 82 million new cases each year. Particularly high rates are seen in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the context of growing infection rates, escalating drug resistance and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US FDA in December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Data and Global Access

According to data released by a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses two antibiotics. The research enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors treating patients have shared positive views. Access to a one-pill regimen of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea globally.